Activity esorubicin recurrent malignant lymphoma Southwest Oncology Group study phase II trial esorubicin deoxydoxorubicin Southwest Oncology Group assessable patients non-Hodgkin lymphoma NHL Hodgkin disease HD time first relapse Esorubicin dose levels patients risk excessive myelosuppression others intervals Overall patients treatment complete remissions CRs partial remissions PRs median duration response months Response rates histologic subtype patients favorable NHL patients unfavorable NHL patients HD Twelve patients durable remissions years Leukopenia cells microliter patients severe cells microliter patients Clinical signs symptoms congestive heart failure ejection fraction EF patients Esorubicin active agent patients NHL HD time first relapse 